Antonio P. Passaro
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 178 publications
Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: August 24, 2026
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 15, 2026
Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 23, 2026
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 20, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.
Journal: ESMO open
Published: March 10, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.
Journal: Cancer treatment reviews
Published: March 06, 2026
First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 01, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 26, 2026
Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 13, 2026
Epidermal Growth Factor Receptor (EGFR) atypical mutations in Non-Small-Cell Lung Cancer (NSCLC): 'where the streets have no name'.
Journal: Critical reviews in oncology/hematology
Published: February 03, 2026
Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.
Journal: Critical reviews in oncology/hematology
Published: February 03, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.
Journal: Cancer
Published: December 16, 2025
Last Updated: 09/26/2026